03:22 AM EDT, 10/27/2026 (MT Newswires) -- Swedish Orphan Biovitrum (SOBI.ST), or Sobi, lifted its revenue growth guidance for full-year 2026, according to a Tuesday release. The Swedish pharmaceuticals company now expects revenue to increase by high-teens to low-20% at constant exchange rate, compared with a mid- to high-teens percentage growth projected previously.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.